The CA 125 (Ovarian CA) ECLIA test is a blood test that measures the level of the CA 125 protein, which can be elevated in various conditions, including ovarian cancer. Using ElectroChemiluminescence Immunoassay (ECLIA) technology, this test offers sensitive and accurate results. Elevated CA 125 levels may suggest the presence of ovarian cancer but can also be linked to other conditions such as endometriosis or pelvic inflammatory disease.

While the CA 125 test is not a definitive diagnostic tool, it is valuable for monitoring treatment progress in ovarian cancer patients, particularly those undergoing chemotherapy or other targeted therapies, as well as for evaluating symptoms indicative of ovarian abnormalities. This test may also be recommended for individuals with a strong family history of ovarian cancer or those carrying inherited genes that increase their risk, particularly for early detection. The scheduling of this test often depends on individual risk factors, but it is commonly utilized during and after cancer treatment to assess cancer status.